These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35172617)

  • 1. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
    Taramasso L; Lo Caputo S; Magnasco L; Briano F; Poliseno M; Bruno SR; Ferrara S; Pincino R; Sarteschi G; Beltramini S; Sasso E; Mora S; Giacomini M; Bassetti M; Di Biagio A
    AIDS Res Hum Retroviruses; 2022 Jun; 38(6):472-479. PubMed ID: 35172617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
    Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
    Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
    BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
    Gagliardini R; Bandera A; Zaccarelli M; Sterrantino G; Latini A; D'Avino A; Lapadula G; Antinori A; Cauda R; De Luca A; Gori A; Di Giambenedetto S; Fabbiani M
    Antivir Ther; 2018; 23(2):139-148. PubMed ID: 28799920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
    Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
    Chang HM; Chou CH; Tsai HC
    BMC Infect Dis; 2022 Jan; 22(1):2. PubMed ID: 34983388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
    Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
    Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
    Mu Y; Pham M; Podany AT; Cory TJ
    Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
    [No Abstract]   [Full Text] [Related]  

  • 10. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
    Taramasso L; Berruti M; Briano F; Di Biagio A
    AIDS; 2020 May; 34(6):877-881. PubMed ID: 32271252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
    PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.
    Bernaud C; Khatchatourian L; Rodallec A; Hall N; Perre P; Morrier M; Pineau S; Jovelin T; André-Garnier E; Raffi F; Allavena C
    Infect Dis (Lond); 2016 Oct; 48(10):754-9. PubMed ID: 27389932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
    Ogbuagu O
    Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.